PLERIXAFOR INJECTION DIN 02490846
Health Canada record
| Active ingredient(s) | PLERIXAFOR 20 MG |
|---|---|
| Dosage form | Solution |
| Route | Subcutaneous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L03AX16 PLERIXAFOR |
| Original market date | |
| Current status date | 02-Aug-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Fresenius Kabi Canada Ltd. — licence 102232, currently licensed, last inspection rating C (2025-10-01).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PLERIXAFOR
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02529815 | PLERIXAFOR INJECTION | JAMP PHARMA CORPORATION | Solution | PLERIXAFOR 20 MG | Marketed |
| 02539454 | PLERIXAFOR INJECTION | EUGIA PHARMA INC. | Solution | PLERIXAFOR 20 MG | Marketed |
| 02377225 | MOZOBIL | SANOFI-AVENTIS CANADA INC | Solution | PLERIXAFOR 20 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 28690 | 2022-08-02 | Abbreviated New Drug Submission (ANDS) |
International API supply for PLERIXAFOR
8 active FDA Drug Master Files.
Request a quote for PLERIXAFOR INJECTION